Fundraising FoxScancell Holdings Plc
2 known investors
Find your way into Scancell Holdings Plc
Sign up to see every warm intro you have to Scancell Holdings Plc
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Scancell Holdings Plc team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Scancell is a UK clinical-stage biotechnology company developing off-the-shelf active immunotherapies for cancer using its Immunobody and Moditope platforms, with a lead melanoma product (iSCIB1+) and a solid-tumour candidate (Modi-1). Through its subsidiary Glymab Therapeutics, it is also developing GlyMab and AvidiMab antibody technologies targeting tumour-specific glycans for solid cancers.
Founders & leadership
Board
Investors · 2
How we know: Seneca Partners's portfolio page · Not right? Tell us
How we know: press coverage · Not right? Tell us
Founder mafia
2 people who came through Scancell Holdings Plc went on to found or lead other companies.
Frequently asked questions
- What does Scancell Holdings Plc do?
- Scancell is a UK clinical-stage biotechnology company developing off-the-shelf active immunotherapies for cancer using its Immunobody and Moditope platforms, with a lead melanoma product (iSCIB1+) and a solid-tumour candidate (Modi-1). Through its subsidiary Glymab Therapeutics, it is also developing GlyMab and AvidiMab antibody technologies targeting tumour-specific glycans for solid cancers.
- Who founded Scancell Holdings Plc?
- Scancell Holdings Plc was founded by Professor Lindy Durrant, Lindy Durrant.
- Who are Scancell Holdings Plc's investors?
- Scancell Holdings Plc's investors include Seneca Partners, BlackRock.